Daily Cardiology Research Analysis
Among 105 cardiology papers, three stood out for immediate clinical relevance and methodological rigor: a meta-analysis of randomized trials comparing balloon-expandable versus self-expanding valves in TAVR, a landmark analysis from PARADISE-MI showing 2-week NT-proBNP strongly predicts subsequent events, and a CMR study demonstrating age- and sex-dependent remodeling in chronic aortic regurgitation with implications for surgical thresholds. These studies refine device selection, enable biomarke
Summary
Among 105 cardiology papers, three stood out for immediate clinical relevance and methodological rigor: a meta-analysis of randomized trials comparing balloon-expandable versus self-expanding valves in TAVR, a landmark analysis from PARADISE-MI showing 2-week NT-proBNP strongly predicts subsequent events, and a CMR study demonstrating age- and sex-dependent remodeling in chronic aortic regurgitation with implications for surgical thresholds. These studies refine device selection, enable biomarker-guided post-MI risk stratification, and support sex- and age-specific imaging criteria.
Research Themes
- Transcatheter valve therapy optimization
- Biomarker-guided risk stratification after myocardial infarction
- Sex- and age-specific imaging thresholds in valvular heart disease
Selected Articles
1. Short-Term, Mid-Term, and Long-Term Outcomes of Transcatheter Aortic Valve Replacement With Balloon-Expandable Versus Self-Expanding Valves: A Meta-Analysis of Randomized Controlled Trials.
Across 10 randomized trials (N=4,325), balloon-expandable valves reduced 30-day cardiovascular and all-cause mortality, moderate–severe PVL at short and long term, and pacemaker implantation versus self-expanding valves, while SEVs achieved larger orifice areas and lower gradients. Signals of higher clinical valve thrombosis with BEVs in mid/long term were based on limited studies.
Impact: This RCT-only meta-analysis provides the most rigorous comparative effectiveness data to date guiding device selection in TAVR, balancing clinical outcomes against hemodynamic performance.
Clinical Implications: For patients at risk of PVL and conduction disturbances, BEVs may be preferred to reduce short-term mortality, PVL, and pacemaker need; SEVs may be favored when maximizing effective orifice area and minimizing gradients. Vigilance for valve thrombosis is warranted with BEVs over longer follow-up.
Key Findings
- At 30 days, BEV reduced cardiovascular mortality (RR 0.56) and all-cause mortality (RR 0.54) versus SEV.
- Moderate–severe PVL was lower with BEV at short term (RR 0.28) and long term (RR 0.28).
- Permanent pacemaker implantation was less frequent with BEV at short term (RR 0.56) and midterm (RR 0.78).
- SEVs achieved larger effective orifice areas and lower mean gradients at all timepoints.
- Limited data suggested higher clinical valve thrombosis with BEV at mid/long term.
Methodological Strengths
- Included only randomized controlled trials with predefined short-, mid-, and long-term endpoints
- Random-effects meta-analysis with pooled risk ratios and mean differences across multiple outcomes
Limitations
- Heterogeneity in valve generations and procedural techniques across trials
- Limited number of studies reporting clinical valve thrombosis in mid/long term
Future Directions: Head-to-head contemporary device trials with standardized antithrombotic strategies and core-lab adjudication of PVL and thrombosis; patient-level meta-analyses to tailor device choice to anatomy and conduction risk.
BACKGROUND: Comparisons of outcomes after transcatheter aortic valve replacement with balloon-expandable (BEV) versus self-expanding (SEV) valves are limited. HYPOTHESIS: This study aimed to compare clinical and hemodynamic outcomes of BEV and SEV at short-term (30 days), midterm (1 year), and long-term (> 1 year) endpoints. METHODS: PubMed, Embase, Scopus, and Cochrane Library databases were searched until July 2024 for randomized controlled trials. Random-effect model (DerSimonian-Laird method) was used to pool the risk ratios (RR), mean differences, and 95% confidence intervals (CI). RESULTS: A total of 10 studies comprising 4325 patients (2295 BEV, 2030 SEV) were included. In short-term, cardiovascular (RR: 0.56, 95% CI: 0.36-0.87) and all-cause mortality (RR: 0.54, 95% CI: 0.35-0.81) were lower in the BEV group. Risk of moderate to severe paravalvular leak (PVL) was lower among BEV patients in short-term (RR: 0.28, 95% CI: 0.17-0.49) and long-term (RR: 0.28, 95% CI: 0.1-0.79). A limited number of studies showed a greater risk of clinical valve thrombosis on BEV in midterm and long-term. The need for permanent pacemaker implantation was lower in BEV at both short-term (RR: 0.56, 95% CI: 0.37-0.87), and midterm (RR: 0.78, 95% CI: 0.64-0.94). The SEV group had a larger effective orifice area with lower mean transvalvular pressure gradient at all endpoints. CONCLUSIONS: BEV is associated with reduced risk of clinical outcomes in short-term; however, most differences diminish in longer evaluations, except for moderate to severe PVL, which remains elevated for SEV. SEVs had better hemodynamic results and lower risk of clinical valve thrombosis.
2. NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial.
In a landmark analysis of 1,062 PARADISE-MI participants free of HF events by week 2, higher NT-proBNP at 2 weeks independently predicted cardiovascular death or incident HF (aHR 1.65 per doubling), HF hospitalization (1.87), recurrent MI (1.46), and all-cause death (1.85), beyond baseline NT-proBNP and clinical covariates.
Impact: The study defines a clinically actionable timepoint—2 weeks post-MI—where NT-proBNP robustly stratifies risk, informing intensified follow-up and preventive therapy.
Clinical Implications: Measuring NT-proBNP at approximately 2 weeks after high-risk MI can guide early intensification of GDMT, closer surveillance, and referral for advanced HF prevention strategies in patients with elevated levels.
Key Findings
- Median 2-week NT-proBNP was 1391 ng/L; highest quartile (≥2507 ng/L) had worse clinical profiles.
- Per doubling of week-2 NT-proBNP, adjusted HRs were 1.65 for CV death/incident HF and 1.87 for HF hospitalization.
- Higher 2-week NT-proBNP also predicted recurrent MI (aHR 1.46) and all-cause death (aHR 1.85), independent of baseline NT-proBNP.
Methodological Strengths
- Landmark design minimizing reverse causation by excluding early HF events
- Multivariable Cox models adjusted for LVEF, baseline NT-proBNP, atrial fibrillation, and clinical covariates
Limitations
- Secondary analysis limited to patients with available week-2 NT-proBNP and no early HF events
- Observational association cannot establish causality or optimal intervention thresholds
Future Directions: Prospective studies testing NT-proBNP-guided care pathways at 2 weeks post-MI to reduce incident HF and recurrent events; integration with imaging or multi-biomarker panels.
BACKGROUND: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with heart failure (HF) hospitalizations and death when measured during a myocardial infarction (MI). However, NT-proBNP concentrations change following the initial ischemic insult and less is known about the prognostic importance of NT-proBNP in the early convalescent phase. METHODS: PARADISE-MI randomized 5661 patients with MI complicated by LVEF ≤40% and/or pulmonary congestion to sacubitril/valsartan or ramipril. Patients with available week 2 NT-proBNP concentrations and without-incident HF between randomization and week 2 (n = 1062) were analyzed. Associations of week 2 NT-proBNP with subsequent clinical outcomes were evaluated in landmark analyses using Cox models adjusted for clinical characteristics, including LVEF, baseline NT-proBNP and atrial fibrillation. RESULTS: Median 2-week NT-proBNP concentration was 1391 [676-2507] ng/L. Patients in the highest NT-proBNP quartile (≥2507 ng/L) were older, had lower left ventricular ejection fraction (LVEF) and estimated glomerular filtration rate (eGFR), higher Killip class, and more atrial fibrillation. Higher NT-proBNP concentrations were independently associated with greater risk of cardiovascular death or incident HF (adjusted hazard ratio [aHR], 1.65 per doubling of NT-proBNP; 95% confidence interval [CI], 1.31-2.09), HF hospitalization (aHR, 1.87; 95% CI, 1.38-2.54), recurrent myocardial infarction (aHR, 1.46; 95% CI, 1.09-1.95) and all-cause death (aHR, 1.85; 95% CI, 1.35-2.53). CONCLUSIONS: Patients with elevated NT-proBNP concentrations approximately 2 weeks after a high-risk myocardial infarction are at heightened risk of incident HF, recurrent coronary events, and death independent of baseline NT-proBNP concentrations and clinical characteristics. Elevations in NT-proBNP concentrations in the early convalescent phase may assist in risk stratification and the identification of patients in need of more advanced preventive treatment approaches.
3. Influence of age and sex on left ventricular remodelling in chronic aortic regurgitation.
In 290 chronic AR patients assessed by CMR, the relationships among regurgitant fraction, regurgitant volume, and LV remodeling were age- and sex-dependent: women and older patients had higher RF for a given RVol, less LV volumetric dilation, but larger diameters and more spherical ventricles. LV diameters underperformed in identifying severe AR in women, supporting age- and sex-specific volumetric thresholds.
Impact: Findings challenge one-size-fits-all cutoffs and argue for sex- and age-specific volumetric thresholds to grade AR severity and guide surgical referral.
Clinical Implications: In women and older patients with AR, reliance on LV diameters risks under-recognition of severe disease; CMR-derived volumetric thresholds tailored by sex and age may better standardize severity grading and timing for surgery.
Key Findings
- RF–RVol correlation was age- and sex-dependent; for the same RVol, RF was higher in women and older patients.
- Women showed less increase in LV-EDVi and LV-ESVi with AR severity, yet had larger LV diameters and greater sphericity.
- LV diameters failed to accurately identify severe AR in females; age- and sex-specific LV volume thresholds provided more consistent assessment.
Methodological Strengths
- Comprehensive CMR assessment across 290 consecutive AR patients over a long enrollment period
- Direct volumetric quantification allowing detailed analysis of remodeling patterns by sex and age
Limitations
- Single-center, prospective cross-sectional design limits generalizability
- Women were underrepresented (19%), which may affect precision of sex-specific estimates
Future Directions: Validate sex- and age-specific LV volumetric thresholds prospectively across diverse cohorts and link to clinical outcomes and surgical timing; integrate with echocardiographic criteria.
AIMS: Aortic regurgitant volumes (RVol) and left ventricular (LV) dimensions and volumes are essential parameters for assessing the severity and guiding surgical timing in aortic regurgitation (AR). However, normal LV volumes vary with age and sex, potentially affecting the interpretation of dilation. This study investigated the impact of sex and age on LV remodelling in chronic AR using cardiac magnetic resonance (CMR). METHODS AND RESULTS: This monocentric prospective cross-sectional study enrolled 290 consecutive adult patients (mean age 51 ± 16 years, 19% women) with chronic at least moderate AR by echocardiography between 2003 and 2022 to undergo a comprehensive CMR examination for evaluation of AR severity and LV remodelling. The correlation between regurgitant fraction (RF) and RVol was age and sex dependent, as both absolute but also body surface indexed RVol represented a higher RF in women and older patients. Also, women had less dilated ventricles and LV-EDVi and LV-ESVi increased less with increasing AR severity in females and with advancing age. Therefore, LV volumes and RVol underestimated AR severity by RF in such patients. However, women had larger LV diameters and more spherical ventricles. Therefore, LV diameters failed to accurately identify severe AR among females as opposed to males. Comparatively, age- and sex-specific LV volume thresholds could equally assess AR severity across sexes. CONCLUSION: Conventional parameters used to grade AR severity and LV remodelling are significantly influenced by age and sex. This encourages the use of age- and sex-specific volumetric thresholds for LV dilation monitoring and surgical referral in AR patients.